Angststörungen
Studienlage · Detail Meta-Analyse · Angststörungen · 2014

A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies.

Klarer Nutzen GRADE Moderat 299 Zitate
Stichprobek = 31 Studien
n = 112.000 Pat.
Dauerany time - March 2013
KontrolleKein Cannabis-Konsum
EndpunktOdds Ratio
Verblindungunklar
DesignMeta-Analyse
Kernaussage

Kleine positive Assoziation zwischen Angststörungen und Cannabiskonsum (OR 1,24) sowie zwischen Angststörungen und Cannabisnutzungsstörungen (OR 1,68); Cannabiskonsum zu Baseline war mit Angststörungen bei Follow-up assoziiert (OR 1,28).

Zusammenfassung

Meta-Analyse über k=31 Studien (n≈112.000) zur Assoziation zwischen Angststörungen und Cannabis-Konsum. Kleine positive Assoziation: Angst↔Cannabis-Konsum OR=1.24 (95% CI: 1.06-1.45, p=0.006), Angst↔Cannabis Use Disorder OR=1.68 (95% CI: 1.23-2.31, p=0.001). Prospektive Subgruppe (k=5): Baseline-Cannabis-Konsum prädiziert Follow-up-Angst OR=1.28 (95% CI: 1.06-1.54, p=0.01). Adjustiert für Confounder.

P
PopulationAllgemeinbevölkerung (nicht-institutionalisiert), 10 Länder, gepoolt ca. n=112.000
I
InterventionCannabis-Konsum oder Cannabis-Gebrauchsstörungen (CUD)
C
KontrolleKein Cannabis-Konsum
O
OutcomeKleine positive Assoziation zwischen Angststörungen und Cannabiskonsum (OR=1,24; 95%-KI: 1,06–1,45; p=0,006) bzw. CUD (OR=1,68; 95%-KI: 1,23–2,31; p=0,001); Cannabiskonsum zu Baseline assoziiert mit Angst im Follow-up (OR=1,28; 95%-KI: 1,06–1,54; p=0,01)
Vertrauen in die Evidenz
Moderat

Dritte von vier GRADE-Stufen, die Effektschätzung ist wahrscheinlich verlässlich.

Herabgestuft wegen
Publikationsbias
Qualitätsprofil
Größe
Verblindung
Effektstärke Klarer Nutzen
Zitate / Jahr
Autoren
Kedzior KK, Laeber LT
DOI 10.1186/1471-244x-14-136
Design: Meta-Analyse
Teilen
Abstract
Background: The aim of the current study was to investigate the association between anxiety and cannabis use/cannabis use disorders in the general population. Methods: A total of N = 267 studies were identified from a systematic literature search (any time- March 2013) of Medline and PsycInfo databases, and a hand search. The results of 31 studies (with prospective cohort or cross-sectional designs using non-institutionalised cases) were analysed using a random-effects meta-analysis with the inverse variance weights. Lifetime or past 12-month cannabis use, anxiety symptoms, and cannabis use disorders (CUD; dependence and/or abuse/harmful use) were classified according to DSM/ICD criteria or scores on standardised scales. Results: There was a small positive association between anxiety and either cannabis use (OR = 1.24, 95% CI: 1.06-1.45, p = .006; N = 15 studies) or CUD (OR = 1.68, 95% CI: 1.23-2.31, p = .001; N = 13 studies), and between comorbid anxiety + depression and cannabis use (OR = 1.68, 95% CI: 1.17-2.40, p = .004; N = 5 studies). The positive associations between anxiety and cannabis use (or CUD) were present in subgroups of studies with ORs adjusted for possible confounders (substance use, psychiatric illness, demographics) and in studies with clinical diagnoses of anxiety. Cannabis use at baseline was significantly associated with anxiety at follow-up in N = 5 studies adjusted for confounders (OR = 1.28, 95% CI: 1.06-1.54, p = .01). The opposite relationship was investigated in only one study. There was little evidence for publication bias. Conclusion: Anxiety is positively associated with cannabis use or CUD in cohorts drawn from some 112,000 non-institutionalised members of the general population of 10 countries.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel